Based on ratings from 0 stock analysts, the InfuSystem Holdings Inc stock price is expected to increase by 58.23% in 12 months. This is calculated by using the average 12-month stock price forecast for InfuSystem Holdings Inc. The lowest target is $12.5 and the highest is $15. Please note analyst price targets are not guaranteed and could be missed completely.
InfuSystem Holdings Inc has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that InfuSystem Holdings Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of INFU.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
B. Riley Securities | Buy | $13 | Initiates | Sep 26, 2024 |
James Terwilliger Northland Capital Markets | Outperform | $27 | Initiates | Apr 26, 2021 |
Craig-Hallum | Buy | Initiates | Aug 31, 2020 |
When did it IPO
2007
Staff Count
499
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Richard A. DiIorio
Market Cap
$202.7M
In 2023, INFU generated $125.8M in revenue, which was a increase of 14.44% from the previous year. This can be seen as a signal that INFU's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - InfuSystem Holdings, Inc. will host its Q3 2024 financial results conference call on November 7, 2024, at 9:00 AM ET. Key executives will participate in the call.
Why It Matters - The Q3 2024 results call for InfuSystem provides insights into the company's financial health, growth prospects, and strategic direction, directly influencing investor sentiment and stock performance.
Summary - InfuSystem has released its financial results for the third quarter of 2024. Further details can be found in their official report.
Why It Matters - InfuSystem's Q3 2024 financial results provide insights into its performance, affecting stock valuations and investor confidence based on revenue growth, profitability, and market position.
Summary - InfuSystem will announce its third quarter 2024 financial results on November 7, 2024.
Why It Matters - The scheduled financial results report can influence investor sentiment, potentially impacting stock price and trading volume based on performance expectations.
Summary - The medical device market is expected to surpass $600 billion by 2025, driven by an aging population, rising healthcare costs, and advancements in AI and biotechnology.
Why It Matters - Projected growth of the medical device market to over $600 billion indicates strong investment potential, driven by demographic trends and technological innovations, signaling robust opportunities for profit.
Summary - InfuSystem will participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024, providing an opportunity for investor engagement.
Why It Matters - InfuSystem's participation in the Lytham Partners Fall 2024 Investor Conference signals potential visibility and engagement with investors, which may impact stock performance and investor interest.
Summary - InfuSystem Holdings, Inc. and Sanara MedTech have signed an exclusive U.S. distribution agreement with ChemoMouthpiece, LLC, enhancing their outpatient care offerings.
Why It Matters - The exclusive distribution agreement with ChemoMouthpiece expands InfuSystem's service offerings, potentially increasing revenue streams and market share, which can positively impact stock performance.